Mbx biosciences announces positive phase 1 topline results for mbx 1416 for the treatment of post-bariatric hypoglycemia

Phase 1 results support proceeding to phase 2 in patients with post-bariatric hypoglycemia (pbh) , which is expected to begin in 2h 2025

MBX Ratings Summary

MBX Quant Ranking